New dialysis fluid may slow hardening of arteries in kidney patients
NCT ID NCT07163936
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether a citrate-based dialysis fluid with extra magnesium can slow or prevent blood vessel hardening in adults on long-term hemodialysis. Eighty stable patients will receive either the new fluid or a standard one for 12 months. Researchers will measure blood markers of calcification risk and monitor heart problems.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
citrate-based dialysate with magnesium
What this could lead to
If it works, this could point toward a safer dialysis fluid that reduces heart problems and death in kidney patients.
What could go wrong
This is a small, early-stage study with only 80 participants, so results may not apply to everyone. The intervention only changes the dialysis fluid, so any benefit is likely modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMODIALYSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••